


CTRL

HH-Ab TREATED

CTRL

FIG. 1A




5 WEEKS OLD MICE

FIG. 1B



ANTI-HEDGEHOG Ab  
FIG. 1D



CTRL Ab  
FIG. 1C



HH-Ab TREATED E18.5

FIG. 1F



CTRL E18.5

FIG. 1E



FIG. 1G



FIG. 1H

5/11



HH-Ab TREATED AT d17

FIG. 1J



CTRL d17

FIG. 1I

FOOTED" 06440360

6/11




FIG. 2

REF ID: A640860

7/11



HH-Ab TREATMENT AFTER BIRTH  
AND CONTINUED TO d10

FIG. 3B




CTRL AT d2

FIG. 3A

CTRL MICE

8/11




SUSPENDED-TREATMENT MICE

CONTINUOUS-TREATED MICE

FIG. 4A

5 WEEKS OLD



CONTINUOUS-TREATED MICE

SUSPENDED MICE

CTRL MICE

FIG. 4B

09004490.034201






FIG. 5

CONSENSUS SEQUENCE OF N-terminal fragments

SEQ ID NO. 4

1	CGPGR <sub>x1</sub>	x2	x3	x4	x5	RR <sub>x6</sub>	x7	x8	K <sub>x9</sub> L <sub>x10</sub> P	L <sub>x11</sub> YKQF <sub>x12</sub> P <sub>x13</sub> V	x14	EKTLGASGR	40		
	x15	EGK <sub>x16</sub>	x17	R <sub>x18</sub> SE		RFK <sub>x19</sub> L <sub>x20</sub> P	PNYN			PDIIFKDEEN	x21	GADRLMT <sub>x22</sub> R	80		
	CK <sub>x23</sub>	x24	x25	NSLAI		x26	VMN <sub>x27</sub>	WPGVK		LRVTEGWDED	GHH <sub>x28</sub>	x29	x30	SLHY	120
	EGRAVDITTS					DRDR <sub>x31</sub>	KYG <sub>x32</sub> L			ARLAVEAGED	WVYYES <sub>x33</sub>	x34	H <sub>x25</sub>		160
	H <sub>x36</sub>	SVK <sub>x37</sub>	x38	x39	S <sub>x40</sub>	AA <sub>x41</sub>	x42	GG							

9/11

FIG. 5A

FIG. 5A

Where:

- X1 is either V or G;
- X2 is either V, F or P;
- X3 is either G or V;
- X4 is either S or G;
- X5 is either R or K;
- X6 is either P, H or Y;
- X7 is either P or A;
- X8 is either R or K;
- X9 is any amino acid;
- X10 is either V or T;
- X11 is either A or L;
- X12 is either S, I or V;
- X13 is either N or G;
- X14 is either P or A;
- X15 is either Y or A;
- X16 is either I or V;
- X17 is either A or S;
- X18 is either S, N or G;
- X19 is either E or D;
- X20 is either T or V;

FIG. 5B

FO2FEC05440860

FIG. 5C

FIG. 5C